O câncer cervical afeta desproporcionalmente pacientes em países em desenvolvimento e é uma das principais causas de morte na América Latina. 📲 Confira a matéria completa: tinyurl.com/3548yjkh #ESMO2023 #ESMO23 #ESMO #ONCONEWSnoESMO23

For as long as I live I will never forget that we have created a world where children have to hold a press conference saying they want to live.

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md/465pj91 #AHA23 AHA Science

It is a great pleasure to share the first publication of our #sarcoma group within LACOG - Latin American Cooperative Oncology Group, discussing challenges and opportunities for sarcoma care and research in Latin America. Hope you enjoy the read, let's work to change the paradigm in Fig 2! thelancet.com/journals/lanam…

Our editorial addressing the challenges & opportunities of the Phase I Clinical Trials 🧬 scenario in Latin America is out! Mirella Nardo, MD SBOC 🇧🇷 JIPO Editors Aung Naing ⁦MD Anderson Cancer Center⁩ meridian.allenpress.com/innovationsjou…

.⁦ESMO - Eur. Oncology⁩ is launching a monthly virtual journal club. 3 papers discussed during 1h by the best experts. The goal is to update all colleagues about the latest advances wherever they are in the 🌍. First session on May ! Stay connected ! esmo.org/about-esmo-mee…

Important point on the MoA of ADCs by Pat LoRusso. Radiolabeled antibody studies showed <1% of tumor uptake with antibody therapies. Elisabeth de Vries

Claudin-18 isoform 2-specific CAR T-cell therapy vs treatment of physician’s choice for advanced GC/GJC The Lancet doi.org/10.1016/S0140-… 🔎 CT041-ST-01 phs 2 trial 👉first 🗺️randomised controlled trial of CAR T-cell therapy in solid tumours 👉Sign improved PFS ESMO - Eur. Oncology

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study -The Lancet Oncology thelancet.com/journals/lanon…

Wild—Bernie Sanders asks: “On one side we have the American Medical Association, American Academy of Pediatrics, and American Public Health Association experts saying vaccines safe and effective, who is on your side? RFK Jr: um um… [names a few whackos]

The LACOG Lung Group, is recruiting patients for the TROPICAL-1 (LACOG 0823). This is a single-arm, phase 2 study of datopotamab deruxtecan, carboplatin and pembrolizumab for treatment-naive, active brain metastases from non-squamous Non-Small Cell Lung Cancer and PD-L1 < 50%.

In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. ALASCCA phase 3 trial results: nej.md/4mpKXNp Editorial: An Aspirin a Day for Improved

Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma. ja.ma/47IArNv

In patients with localized colorectal cancer and PIK3CA hotspot mutations in exon 9 or 20, daily low-dose aspirin resulted in a significantly lower recurrence rate than placebo. Full ALASCCA phase 3 trial results and Research Summary: nej.md/4mpKXNp

I fear the public will never truly realize the immense damage done to our scientific research system and its consequences. A loss of ~$4.5 billion in frozen or cancelled grants with at least 148 impacted clinical trials = 138,000 patients due to be enrolled or already enrolled.

👏 Congrats Vivek Subbiah, MD & team on their important study in @JCOOA_asco 👉 how U.S. FDA Project Optimus is transforming early-phase oncology trials — shifting focus from “maximum tolerated dose” to smarter, patient-centered designs👉huge step forward for cancer research!

Bayesian Designs such as BOIN surpassed 3+3 as the most frequent phase I design. An overall trend towards the adoption of faster, safer, smarter and more patient-centric designs, following FDA Project Optimus. Great for both patients and scientific community!

The LACOG Gynecology Group, in collaboration with GOG Foundation (The GOG Foundation Inc. ) and EVA - Brazilian Group of Gynecological Tumors (EVA - Brazilian Gynecologic Oncology Group), is recruiting patients for the DESTINY-Endometrial01 (LACOG 0124 - EVA | GOG-3098) trial. #LACOG #SomosTodosEVA #GynecologicalGroup

Ben Bleiberg #TumorBoardTuesday I was kind of amazed at how quickly SQ Ami was put out there I think J&J deserves credit (unless I don't know the whole story) for not milking the IV patent life and just sitting on the SQ formulation - but instead getting SQ out there quickly

Here a great example of an ethical trial….crossover to standard current second line therapy #SacituzumabGovitecan allowed and offered by the company Gilead Sciences 👏👏🙌🙌 OncoAlert ESMO - Eur. Oncology ASCO FDA EORTC